RBC Europe’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

RBC Europe’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-580	Closed	-$4.42K	–	1234
2021 Q3	$4.42K	Hold	580	–	–	﹤0.01%	1057
2021 Q2	$5.62K	Hold	580	–	–	﹤0.01%	1039
2021 Q1	$4.8K	Hold	580	–	–	﹤0.01%	1003
2020 Q4	$3.96K	Hold	580	–	–	﹤0.01%	998
2020 Q3	$6.47K	Hold	580	–	–	﹤0.01%	873
2020 Q2	$3.64K	Buy	+580	New	+$2.22K	﹤0.01%	900

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

RBC Europe's SRNE Position: Q4 2021 in Review

RBC Europe sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2021, closing a stake of 580 shares — an estimated $4.42K sold.

RBC Europe first reported a position in SRNE in Q2 2020 and held it in 6 quarters. The position peaked at $6.47K in Q3 2020. 234 funds tracked by Wall St. Rank hold SRNE as of Q4 2021.

RBC Europe reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 580 Sorrento Therapeutics, Inc. shares in Q4 2021, an estimated $4.42K.
RBC Europe first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 6 quarters.
RBC Europe's Sorrento Therapeutics, Inc. position peaked at $6.47K in Q3 2020.
234 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.